Scarica l'app Stockscreener
8.41
10.51%
0.80
Dopo l'orario di chiusura:
8.43
0.02
+0.24%
Replimune Group Inc Borsa (REPL) Ultime notizie
Replimune Group Inc. Faces Mixed Market Reactions Amid Financial Updates - timothysykes.com
Replimune Group Inc. Stock Dips Amid Financial Challenges and Market Pressures - timothysykes.com
REPL PE Ratio & Valuation, Is REPL Overvalued - Intellectia AI
Replimune, Grace among biotechs with April PDUFA dates - biocentury.com
REPL files Form 144 notice (NASDAQ: REPL) with RSU vesting details - Stock Titan
Replimune Group Inc (7R8.SG) stock price, news, quote and history - Yahoo Finance Singapore
Replimune Group (NASDAQ:REPL) Shares Up 7.2%Should You Buy? - marketbeat.com
Replimune Shares Approach a Pivotal Regulatory Verdict - AD HOC NEWS
Meme Stocks: Can Replimune Group Inc expand its profit margins2026 Snapshot & AI Driven Price Predictions - baoquankhu1.vn
Entry Recap: Is Replimune Group Inc stock undervalued right now2026 Price Targets & Verified Swing Trading Watchlists - baoquankhu1.vn
Replimune Group (FRA:7R8) PB Ratio : 2.79 (As of Mar. 28, 2026) - GuruFocus
Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Wall Street analysts predict a 65.72% upside in Replimune Group (REPL): Here's what you should know - MSN
Aug Update: Is now the right time to enter Replimune Group Inc2026 Price Momentum & Community Consensus Trade Signals - baoquankhu1.vn
Analyst Upgrade: Is IBTA affected by consumer sentiment2026 Performance Recap & Capital Efficiency Focused Ideas - baoquankhu1.vn
REPL Technical Analysis | Trend, Signals & Chart Patterns | REPLIMUNE GROUP INC (NASDAQ:REPL) - chartmill.com
Replimune's Oncolytic Viral Therapy For Melanoma Faces Second Shot At FDA Approval - RTTNews
Replimune Shares Skyrocket After FDA Accepts Resubmitted BLA for Melanoma Therapy - MSN
Aug PostEarnings: Does Replimune Group Inc align with a passive investing strategyWeekly Trading Summary & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Does Replimune Group (REPL) have the potential to rally 79.61% as Wall Street analysts expect? - MSN
Fcpm Iii Services B.V. Boosts Position in Replimune Group, Inc. $REPL - MarketBeat
Institutional Investors Double Down on Replimune Amid Market Turmoil () - aktiencheck.de
Boxer Capital Management LLC Has $4.40 Million Stock Holdings in Replimune Group, Inc. $REPL - MarketBeat
Braidwell LP Boosts Stock Holdings in Replimune Group, Inc. $REPL - MarketBeat
Quinn Opportunity Partners LLC Invests $2.73 Million in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group (NASDAQ:REPL) Stock Price Down 8%Here's What Happened - MarketBeat
Wedbush Upgrades Replimune Group (REPL) - MSN
REPL: Awaiting April 10th PDUFA for RP1, with commercial launch readiness and robust pipeline progress - TradingView
Replimune Group (NASDAQ:REPL) Trading 11.1% HigherHere's Why - MarketBeat
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - Finviz
Replimune Stock Quote, Share Price, News and Analysis - Longbridge
REPL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Does Replimune Group (REPL) Possess the Opportunity to Surge by 79.61% According to Wall Street Analysts' Predictions? - Bitget
Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect? - Finviz
Replimune to Present at Two Upcoming Investor Conferences - The Manila Times
Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Hold" by Analysts - MarketBeat
Erste Asset Management GmbH Increases Stock Position in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group, Inc. (REPL) Stock Analysis: A High-Potential Biotech Play with 67% Upside - DirectorsTalk Interviews
Replimune Group Stock Price Forecast. Should You Buy REPL? - StockInvest.us
Replimune's Pivotal FDA Verdict Approaches - AD HOC NEWS
Market Leaders: Can Replimune Group Inc expand its profit margins2025 Fundamental Recap & Reliable Breakout Forecasts - baoquankhu1.vn
Analyst Calls: Is Apyx Medical Corporation in accumulation or distribution phaseEarnings Miss & Real-Time Volume Analysis - baoquankhu1.vn
Replimune Shares Approach a Pivotal Regulatory Milestone - AD HOC NEWS
Replimune Group, Inc. (REPL) Stock Analysis: Unpacking a 50% Potential Upside in Biotechnology - DirectorsTalk Interviews
Replimune: Multiple Shots On Goal But A High Risk Binary Approaches - Seeking Alpha
What is Replimune Group Inc.’s market positionQuarterly Profit Summary & Precise Swing Trade Entry Alerts - mfd.ru
Replimune Group (REPL) director gifts 25,000 common shares - Stock Titan
Institutional Confidence Surges in Replimune as Key Drug Review Looms - AD HOC NEWS
Replimune Group, Inc. $REPL Shares Purchased by Readystate Asset Management LP - MarketBeat
Replimune rebounds despite analyst downgrades on FDA rejection - MSN
Forbion discloses 3.5% Replimune (REPL) stake in ownership filing - Stock Titan
REPL SEC FilingsReplimune Group 10-K, 10-Q, 8-K Forms - Stock Titan
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):